A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia - Adams, D H; Kinon, B J; Baygani, S (BMC Psychiatry, 2013)
et al.